Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.51 |
| ▸ | GABRD | O14764 | 2/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.51 |
| ▸ | GABRE | P78334 | 2/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937261 | 1.00 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6939423 | 1.00 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6939759 | 0.94 | LMNA (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6939757 | 0.94 | LMNA (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6940791 | 0.94 | SSTR5 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6940797 | 0.94 | SSTR5 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6940047 | 0.93 | NPSR1 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6940044 | 0.93 | NPSR1 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6942070 | 0.93 | NPSR1 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6942073 | 0.93 | NPSR1 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | claimed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | claimed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | GABRP 2830/4885GABRD 1999/4885GABRA1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.